Ghost Tree Capital adds Boston Scientific Corporation (BSX) to its portfolio

Boston Scientific Corporation (BSX) : Ghost Tree Capital added new position in Boston Scientific Corporation during the most recent quarter end. The investment management firm now holds 450,000 shares of Boston Scientific Corporation which is valued at $10.1 Million , the company said in a statement filed on May 13, 2016 with the SEC.Boston Scientific Corporation makes up approximately 8.10% of Ghost Tree Capital’s portfolio.

Other Hedge Funds, Including , Public Sector Pension Investment Board reduced its stake in BSX by selling 125,300 shares or 36.47% in the most recent quarter. The Hedge Fund company now holds 218,311 shares of BSX which is valued at $4.9 Million. Boston Scientific Corporation makes up approx 0.06% of Public Sector Pension Investment Board’s portfolio.Boston Partners reduced its stake in BSX by selling 2,700,827 shares or 25.96% in the most recent quarter. The Hedge Fund company now holds 7,703,438 shares of BSX which is valued at $172.2 Million. Boston Scientific Corporation makes up approx 0.25% of Boston Partners’s portfolio.Manufacturers Life Insurance Company The boosted its stake in BSX in the latest quarter, The investment management firm added 348,566 additional shares and now holds a total of 1,674,510 shares of Boston Scientific Corporation which is valued at $37.4 Million. Boston Scientific Corporation makes up approx 0.06% of Manufacturers Life Insurance Company The’s portfolio.

Boston Scientific Corporation closed down -0.14 points or -0.62% at $22.39 with 86,38,193 shares getting traded on Wednesday. Post opening the session at $22.54, the shares hit an intraday low of $22.32 and an intraday high of $22.62 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

On the company’s financial health, Boston Scientific Corporation reported $0.28 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $0.24. The company had revenue of $1964.00 million for the quarter, compared to analysts expectations of $1912.86 million. The company’s revenue was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.21 EPS.

Many Wall Street Analysts have commented on Boston Scientific Corporation. Company shares were Reiterated by RBC Capital Mkts on Apr 28, 2016 to “Outperform”, Firm has raised the Price Target to $ 25 from a previous price target of $22 .Company shares were Reiterated by Stifel on Apr 28, 2016 to “Buy”, Firm has raised the Price Target to $ 25 from a previous price target of $22 .Company shares were Reiterated by Wedbush on Apr 28, 2016 to “Neutral”, Firm has raised the Price Target to $ 23 from a previous price target of $19 .

Boston Scientific Corporation develops manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology which includes Drug-Eluting Coronary Stent Systems Intravascular Imaging devised and Coronary Technology products such as guide wires guide catheters and balloon catheters among others; Peripheral Interventions (PI) which include stents balloon catheters wires peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM) which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP) which include steerable RF ablation catheters intracardiac ultrasound catheters diagnostic catheters delivery sheaths and other accessories; Endoscopy which includes Spyglass System WallFlex Colonic Stents Resolution Clip and Expect Aspiration Needle among others; Urology and Women’s Health and Neuromodulation.

Leave a Reply

Boston Scientific Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Boston Scientific Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.